FDA Approves AVYCAZ(R) (ceftazidime and avibactam) for the Treatment of Patients with Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia

First Gram-Negative Antibiotic Approved in the U.S. to Treat HABP/VABP in Over 15 Years DUBLIN, Feb. 1, 2018 -- (Healthcare Sales & Marketing Network) -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced that the U.S. F... Biopharmaceuticals, FDA Allergan, AVYCAZ, ceftazidime, avibactam, Bacterial Pneumonia
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news